Servier and ViiV Healthcare to launch HIV drug production in Russia
HIV specialist company ViiV Healthcare, which is majority owned by GlaxoSmithKline (LSE: GSK), has officially launched full-cycle production of an innovative drug for the treatment of HIV in Russia at the facilities of French independent drugmaker Servier’s plant in Moscow, according to recent statements by the Moscow city government, reports The Pharma Letter’s local correspondent.
The drug in question is Tivicay (dolutegravir) and the production contract was signed between the companies for a period of five years. Technical and financial details of the project are not disclosed.
An initiative for the beginning of production of dolutegravir in Russia was for the first time put forward in 2015 after the registration of the drug in the local market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze